180 Life Sciences (NASDAQ:ATNF) Earns “Sell (E+)” Rating from Weiss Ratings

180 Life Sciences (NASDAQ:ATNF)‘s stock had its “sell (e+)” rating reissued by Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

180 Life Sciences Price Performance

Shares of ATNF stock opened at $1.33 on Friday. The business has a 50-day simple moving average of $1.86 and a 200-day simple moving average of $2.19. 180 Life Sciences has a 52-week low of $1.16 and a 52-week high of $17.75.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.